Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 16th Preview)
-
Regulatory approvals – oncology
The FDA approved Merck & Co.’s Welireg (belzutifan) in combination with Keytruda (pembrolizumab) for adjuvant clear cell renal cell carcinoma (ccRCC), marking the first approval for a PD-1 plus HIF-2α inhibitor pairing in this setting. The label covers adults with intermediate-high or high risk of recurrence following kidney removal surgery. The combination is based on Merck’s Litespark-022 pivotal adjuvant trial, in which Welireg plus Keytruda reduced the risk of disease recurrence, metastasis, or death by 28% versus Keytruda and placebo. Merck also pointed to disease-free survival estimates of 81% versus 74% at the reported timepoints, while overall survival data remain immature. The approval extends Welireg’s earlier advanced RCC clearance to earlier-stage disease and strengthens Merck’s post-Keytruda kidney cancer strategy.
-
Medicare pricing and policy – drug payment mechanics
CMS moved to close a Medicare “fixed combination” drug loophole that the agency said can enable manufacturers to extend commercially protected product timelines under the Inflation Reduction Act’s drug price negotiation framework. The proposed rule would codify aspects of the Medicare Drug Price Negotiation Program, update negotiation and benefit policies, and adjust how fixed-combination drugs are handled—an area that could affect lifecycle management strategies for large biotech products. Separate reporting also indicates CMS is preparing future price-negotiation talks that could eventually sweep in newer subcutaneous formulations of blockbuster immunotherapies, including Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, depending on biosimilar entry and selection rules.
-
European regulation – clinical trial process changes
The European Medicines Agency said it is preparing for “major” Clinical Trial Regulation changes tied to the incoming EU Biotech Act, aiming to reduce sponsor administrative burden while speeding assessments. EMA said its management board will allocate resources to update internal systems before the new rules take effect later this year. The changes include greater flexibility for sponsors and CROs to adjust ongoing studies and enhancements to CTIS, the clinical trials information platform. EMA positioned the Biotech Act as part of the broader ACT EU initiative, building on measures already implemented to streamline submissions across EU member states.
-
Biopharma funding and launches – AI drug discovery
Radical Numerics launched with a $50 million seed round led by Emergence Capital as the AI biotech pushes multimodal models trained across DNA, RNA, and proteins. The company said its integrated platform—designed to reason across multiple dimensions of biology—targets applications in cancer diagnostics, drug target identification, and biosecurity. Founders include Eric Nguyen and Michael Poli, creators of the Evo generative genomics model series. Radical Numerics also said it is previewing its next-generation genomic language model, Omnii, and is partnering with an undisclosed cancer diagnostics company to apply the approach to pancreatic and multi-cancer detection.
-
Acquisitions and development programs – blood cancer
Eli Lilly presented encouraging early Phase 1 results for AJ1-11095, a type II JAK2 inhibitor in development for myelofibrosis, at the European Hematology Association meeting. The drug came through Lilly’s acquisition of Ajax Therapeutics, and interim data were framed as supportive of AJ1-11095’s potential role as a next-generation option in a treatment area dominated by JAK inhibitors. Analysts noted the competitive implications, with the potential for AJ1-11095 to challenge Incyte’s Jakafi depending on efficacy, safety, and differentiation versus current standards.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.